» News » Sputnik vaccine shows 92% efficacy

Sputnik vaccine shows 92% efficacy

Last updated on: November 27, 2021 11:49 IST
Get Rediff News in your Inbox:

'A good 30 per cent of people will still get infected after getting the Covishield vaccine.'

IMAGE: A health worker poses for a photograph with the Sputnik V vaccine during a pilot vaccination programme at the Apollo Hospitals Jubilee Hills in Hyderabad, May 17, 2021. Photograph: PicStyle Photo Service/ANI Photo

Daily, we are bombarded with exhaustive details on how to navigate our stressful vaccination situations.

Information on what to do if we have not gotten our second Covishield vaccine.

Or our future if a second Covaxin is not available.

Or how Sputnik's arrival all the way from Russia, on our horizons will surely brighten it.

When a Pfizer vaccine might enter our lives.

Sage advice on the quickest and skillful way to book a vaccine if you are over 18.

The list of hotels you can check in at in Hyderabad and get at a cost, both a restful stay and a vaccine.



In the third part of an enlightening interview with Vaihayasi Pande Daniel/ Dr Priya Sampathkumar, infectious disease expert, practicing at the world famous Mayo Clinic in Rochester, Minnesota, separates wheat from chaff as she sheds some light on the vaccines available, their efficacy and the right timetable.

IMAGE: People queue to get registered for COVID-19 vaccination at the Government High School in Bengaluru, May 31, 2021. Photograph: Shashidhar Byrappa/ANI Photo

What is your assessment of the Sputnik vaccine? Because America has used so much of Pfizer and Moderna, doubts are still being cast on the efficacy of AstraZeneca.
Also because of vaccine shortages what happens if you are not able to get the second dose on time, like my husband?

I would love to talk about that.

So first of all, AstraZeneca is a good vaccine. It's not as effective as Moderna and Pfizer at preventing infection. Moderna and Pfizer are about 95 per cent effective at preventing any kind of infection, including mild infections.

AstraZeneca is roughly around 70 per cent effective at preventing infection. So, a good 30 per cent of people will still get infected after getting the Covishield vaccine.

Now, those infections, though, generally tend to be mild and the risk of dying from COVID-19, after vaccination, is roughly 2 per cent, regardless of the vaccine, so Pfizer Moderna, there's a small risk of dying.

Similarly, with Covishield, there's a small risk of dying -- it doesn't eliminate it, but it reduces it significantly.

The real difference between the mRNA vaccines* and Covishield is the ability to prevent mild infection. Definitely, Covishield is not as good as the mRNA vaccines. So, in terms of preventing infection, it's important that you don't assume that just because you're vaccinated, you don't need to take any precautions.

You still need to mask and protect other people from getting a mild infection from you.

IMAGE: A health worker administers the Sputnik V vaccine to employees of Dr Reddy's Laboratories during a pilot vaccination programme at the Apollo Hospitals Jubilee Hills in Hyderabad, May 17, 2021. Photograph: Pic.Style Photo Service/ANI Photo

About the Sputnik vaccine?

The Sputnik vaccine uses the same platform as the Covishield vaccine. It's a viral vector vaccine. The difference is the type of adenovirus** that's in the Sputnik vaccine that's a human adenovirus.

It's two different strains in Dose 1 and Dose 2, versus in AstraZeneca it's a chimpanzee adenovirus -- really minor differences, but the mechanism of action is the same.

Now, the Sputnik vaccine study was in in Russia, and the vaccines showed about a 92 per cent efficacy overall at preventing infection. And again, close to 100 per cent efficacy at preventing serious illness and death. The data looks good.

I'm a little leery only because the study was only in Moscow, and I'm not sure how well the trial was conducted.

But it was published in a peer-reviewed journal -- it was in The Lancet, a reputed journal. So, their data is at least reasonably sound.

The next question you had is, what about not being able to get the second dose. So, the Covishield vaccine was tried at different dosing intervals. And actually, the longer duration between the two doses was a little bit more efficacious.

So, you know that the Indian government first said (a second dose after) four weeks, and they went to six weeks, and now they're saying, eight to 16 weeks and I think that is the right approach.

The UK government did exactly this. They said: Everyone gets first doses, then we'll give you second doses when possible. And even with one dose, you get so much protection that their case counts dropped dramatically.

So, I think your husband will be fine. Waiting for the second dose, you don't need to restart the series. The second dose is really a booster -- it increases the duration of protection and doesn't really increase the protection.

IMAGE: A COVID-19 patient rests inside the Shehnai Banquet Hall, converted into a COVID-19 isolation centre, in New Delhi, May 25, 2021. Photograph: PTI Photo

In one of your tweets you stated how because of the precautions that were happening in America for COVID-19, the cases of influenza were not that high in the winter.
Can that be applied to India and other respiratory diseases in India like, like lowering TB infectivity rates, although, of course, India doesn't have great mask protocol? But then again, I don't think any country has that great mask protocol.


If there's one silver lining to this whole thing -- we had almost zero influenza during the flu season here. And for us flu is very seasonal. So, between November and February, if you wear a mask, I think we could we could all be safe from influenza.

And this is really important knowledge for us because our influenza -- we have very high vaccination rates in for influenza in the US -- but we still have deaths in some pockets of population and those are highly immunocompromised patients, patients after bone marrow transplants, patients getting cancer chemotherapy.

And we've always said: Well, you know, we just have to accept it because you can't expect people to wear masks all the time.

But I really think maybe we can expect people around these cancer patients, people around the BMT (bone marrow transplant) patients to wear masks all the time. It's for two or three months of the year. It's doable. I think that has really been key learning for us.

And then in India, I think, yes, wearing a mask will definitely reduce the risk of TB. It doesn't eliminate it because of the way TB is transmitted.

TB is truly an airborne infection, so (if you are infected with TB) you can breathe it out. And the TB bacteria will stay in the air in the room that you were in. And someone who comes into the room, up to an hour later could get infected with TB, even though you were not in the room then. So, it won't eliminate it, but it will reduce TB transmission.

*According to CDC US: 'mRNA vaccines are a new type of vaccine to protect against infectious diseases. To trigger an immune response, many vaccines put a weakened or inactivated germ into our bodies. Not mRNA vaccines. Instead, they teach our cells how to make a protein--or even just a piece of a protein--that triggers an immune response inside our bodies. That immune response, which produces antibodies, is what protects us from getting infected if the real virus enters our bodies'.

** Using an adenovirus, another kind of common virus, as a viral vector or tool to make vaccines for other infectious viruses

Feature Presentation: Ashish Narsale/

Get Rediff News in your Inbox: